ClinicalTrials.gg
RecruitingNCT05496296Updated Nov 20, 2025

Comparison of Transforming Powder Dressing to NPIAP Recommended Standard of Care Therapies in Stage 2, 3 and 4 Pressure Injuries

An interventional study of Altrazeal® Transforming Powder Dressing in Pressure Ulcers Stage II, Pressure Ulcers Stage III and Pressure Ulcer, Stage IV, sponsored by ULURU Inc.. Recruiting at 14 sites in United States. Open to participants aged 18 Years to 85 Years, including healthy volunteers. Per ClinicalTrials.gov, last updated 2025-11-20.

Sponsored by ULURU Inc. · Not applicable, Interventional, and Treatment

How we know

From the registry’s dates

  • Started Apr 2023; still recruiting 3 years 6 months later.

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Phase
Not applicable
Study type
Interventional
Enrollment
300
Allocation
Randomized
Ages
18 Years to 85 Years
Sex
All
01

Where this study stands

Counted across the records on this site · 2026-11-22

Among 153 studies in Pressure Ulcer with a site in United States — 25 open to participants now, 28 under way, none of them phase 3. Pressure Ulcer · United States.

Planned enrollment
17th of 118
300 · median 48
Started
2023
with 2 others
No phase
88 of 153
10 open now
Primary completion
2026-12
later than 9 of 27 live
Registered
124th of 153
by date

Among the 153 studies in Pressure Ulcer with a site in United States, this one is the 17th largest by planned enrollment of the 118 interventional ones that give a count, is one of 3 that started in 2023, is one of 88 with no phase, reaches primary completion later than 9 of the 27 other live ones, and was the 124th registered.

Pressure Ulcer

548 studies on the registry are indexed under Pressure Ulcer; 127 are open to participants now.

Browse Pressure Ulcer studies →

Open to participants now

25 of the 153 studies in Pressure Ulcer with a site in United States are open now. Recruiting first, the newest first:

19 more — sign in →

All 25 open studies →

A study can be open while its sites in United States have not opened yet or have stopped. Only those recruiting at a site in United States →

Who these studies take

Of the 61 Pressure Ulcer studies recruiting now, 45 (74%) set no upper age limit and 6 (10%) stop at 75 or younger; 10 take children under 18; 13 take healthy volunteers.

This study: 18 Years to 85 Years · all sexes · healthy volunteers too.

The full table on the hub →

This tab as a report to print or save as PDF → With an account.

Was this useful?
Get alerts for this landscapeDownload CSVNarrow it in search →With an account: a weekly mail of what changed among 153 studies in Pressure Ulcer with a site in United States, or all of them as a file.
02

Study summary

Pressure injuries, commonly known as pressure ulcers, affect over 2.5 million people in the United States. Pressure injuries are classified into four escalating stages, from intact skin to full thickness wounds with deep tissue loss and exposed bone. This study will compare current standard of care treatment (as recommended by the National Pressure Injury Advisory Panel) to treatment with Altrazeal® in patients with stage 2, stage 3 and stage 4 pressure injury wounds. Altrazeal® is a Class 1, 501(k) exempt medical device listed with the FDA as a "dressing, wound, hydrogel" and has an extended wear time of up to 30 days. Subjects can be enrolled in the study either as an outpatient, or while hospitalized. Half of the subjects will be randomized to standard of care treatment, and the other half will be randomized to Altrazeal®. There are a total of up to 12 study visits taking place over 12 weeks.

Read the detailed description

Pressure injuries, commonly known as pressure ulcers, affect over 2.5 million people in the United States. Pressure injuries are classified into four escalating stages, from intact skin with redness to full thickness wounds with deep tissue loss and exposed bone.

This study will focus on patients with stage 2, stage 3 and stage 4 pressure injury wounds. It will compare current standard of care treatment (as recommended by the National Pressure Injury Advisory Panel) to treatment with Altrazeal® Transforming Powder Dressing (TPD). Altrazeal® is a Class 1, 501(k) exempt medical device listed with the FDA as a "dressing, wound, hydrogel" and has an extended wear time of up to 30 days. Altrazeal® is a powder dressing that conforms to the wound, covering and protecting it, shielding the wound from bacteria. Altrazeal® is used in conjunction with a secondary dressing when needed.

The primary aim of the study is to evaluate whether dressing changes can be reduced during treatment of pressure injuries. The study will also compare wound healing between the group receiving Altrazeal® and the group receiving standard of care dressings, as well as complications, pain, quality of life, and overall costs between the two groups.

Subjects will be randomized into 2 groups, standard of care and Altrazeal®. Half of the subjects will receive current standard of care treatment, and the other half will receive treatment with Altrazeal®. This is an open-label study, meaning that both the subject and the treatment provider will know what study group the subject has been randomized to.

The first visit will be the screening visit to ensure patients meet eligibility criteria. Patients can be either an outpatient or hospitalized. Written informed consent will be obtained during this visit. A wound evaluation will be performed, and laboratory work ordered, if not done recently.

Once identified as meeting study criteria, the next visit is Baseline Visit, where randomization will occur and the first treatment will take place. Participants will be evaluated for 12 additional consecutive weeks, receiving wound evaluation, measurements, and getting treatment for the wound. A pain evaluation, quality of life survey related to having a wound, questionnaire regarding additional wound care performed between study visits. Participants will also answer questions regarding how much offloading devices or maneuvers were utilized, medications taken, and if any complications developed related to their wound care.

If the wound is healed prior to 12 weeks, the study will end when the wound is healed. Otherwise, the study will go on for 12 consecutive weeks. At the end of the study, the participant will be asked to complete a Subject Satisfaction Survey, answering questions regarding how the wound dressing worked for them. The surveys should take 5-10 minutes to complete.

03

Conditions studied

  • Pressure Ulcers Stage II
  • Pressure Ulcers Stage III
  • Pressure Ulcer, Stage IV

Keywords

  • Wound care
  • Quality of life
  • Pain
04

Who can participate

Ages eligible
18 Years to 85 Years
Sexes eligible
All
Accepts healthy volunteers
Yes

Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.

Inclusion criteria

  1. 18 to 85 years of age;
  2. Stage 2, 3, or 4 Pressure Injuries;
  3. Wound exudate is mild to moderate;
  4. No clinically active wound infection (clinical diagnosis);
  5. Able and willing to provide written (not proxy) ;
  6. Clinically stable, as determined by assessment of medical history, vital signs, physical examination, and laboratory testing prior to enrollment.

Exclusion criteria

Exclusion Criteria:

  1. Known allergy or to TPD or its components;
  2. Pressure injuries classified as unstageable, deep tissue pressure injury, or Stage 1;
  3. Heavily exudative wounds;
  4. Wound infection as defined as the presence of a least two of the following: local swelling or in duration, erythema >0.5cm around the ulcer in any direction, local tenderness or pain local warmth and purulent discharge;
  5. Poorly controlled diabetes with HgbA1C >12 (as documented in the last 3 months);
  6. (BMI) >45 kg/m2;
  7. Venous stasis disease or lymphedema in the affected limb (if wound is located on the limb);
  8. Moderate to severe chronic limb ischemia Ankle Brachial Index (ABI) \<0.7 on the affected limb, if wound is located on the limb);
  9. Received or biologics in the last six weeks and/or is expected to receive either at any point during the study;
  10. Selected concurrent treatments (e.g., hyperbaric oxygen, topical oxygen therapy, electrical stimulation, ultrasound, cellular or acellular skin substitutes) during study period that may impact study outcomes;
  11. Wounds with necrosis unable to undergo prior definitive debridement;
  12. Fistulas;
  13. Active gangrene;
  14. Untreated ;
  15. Currently pregnant or lactating;
  16. Impending organ transplant;
  17. Vulnerable populations including prisoners, pediatrics, cognitively impaired, unconscious, and illiterate patients;
  18. Unwilling or unable to comply with offloading recommendations;
  19. If, in the opinion of the clinical investigator, a subject is a poor candidate for this study because:

    1. Unable to keep research appointments;
    2. Poorly controlled incontinence which may impact study outcomes (e.g., depending on the location of the wound);
    3. Participated in another investigative study within 3 months of enrollment that could interfere with study outcomes;
    4. Active alcohol or substance abuse (cocaine, heroin, or other substances) that may interfere with healing or subject compliance with visit schedules;
    5. Concurrent clinical condition(s) that could pose a health risk to patient or influence outcome of study;
    6. Not suitable for study participation. -
Terms in these criteria, in plain language(5)

Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.

Informed consent

Before you join, the study team explains what taking part involves — its purpose, what happens, the risks and possible benefits — and answers your questions, so you can decide freely. Consent is usually recorded on a form (the informed consent form, ICF) signed by you or, where the law allows, by someone legally authorized to decide for you.

You can keep asking questions during the study, you are told of new information that matters, and you can choose to leave at any time.

Hypersensitivity

An allergy, or another reaction of the immune system, to a substance. “Hypersensitivity to the study drug” means a known allergic reaction to it — not every side effect a medicine can have.

BMI (body mass index)

Weight in kilograms divided by height in metres squared. Example: 70 kg and 1.75 m gives 70 ÷ (1.75 × 1.75) ≈ 22.9.

What counts as overweight or obesity differs between countries (some use lower cut-offs), so go by the range the study states.

Immunosuppression

A weakened immune system. It can come from an illness, such as HIV or some blood cancers, or from medicines that turn the immune system down, for example after an organ transplant or for an autoimmune disease; steroids at higher doses count.

Read whether the line is about a condition or about medicines, and which medicines and doses it means.

HIV

The human immunodeficiency virus, which weakens the immune system.

Many studies now accept people whose HIV is controlled on treatment, judged by the viral load and the CD4 count. Check the limits this study sets.

05

Study design

Phase
Not applicable
Primary purpose
Treatment
Allocation
Randomized
Intervention model
Factorial assignment
Masking
None (open label)
Enrollment
300 participants (estimated)

Study arms

  • Active comparator
    Standard of Care Dressing for Pressure Injury

    Standard wound dressings recommended by the National Pressure Injury Advisory Panel (NPIAP), according to the wound stage, will be utilized to treat pressure injuries. These include hydrocolloid, hydrogel, polymeric membranes, foam, collagen dressings, and negative pressure wound therapy. Dressings will be changed according to wound conditions, and type of dressing selected.

    Device: Altrazeal® Transforming Powder Dressing

  • Active comparator
    Altrazeal® Transforming Powder Dressing

    Altrazeal® Transforming Powder Dressing will be applied during the Baseline visit. It should be left in place for up to 30 days, and topped off (additional powder applied if needed) at each subsequent visit. Secondary dressing, including a contact layer over the Altrazeal® and a secondary dressing (like gauze or foam) may be applied over the contact layer.

    Device: Altrazeal® Transforming Powder Dressing

Interventions

  • DeviceAltrazeal® Transforming Powder Dressing

    Pressure injury wounds will be evaluated at each study visit (cleaned, photographed, measured) and a dressing will be applied according to the study arm

    Also known as: Standard of Care wound dressings (such as foam, hydrocolloid, collagen, etc)

06

What researchers measure

Primary outcomes

  1. Number of wound dressing changes

    The number of primary dressing changes for each treatment group will be compared.

    Time frame: 12 weeks

Secondary outcomes

  1. Wound healing

    Wound healing will be measured by using a ruler each week to report length and width of the wound. Percentage of wound area reduction will be calculated for each treatment group and compared.

    Time frame: 12 weeks

  2. Complications (problems) from treating the pressure wound

    Subjects will be asked to report, will be questioned and observed (by the researchers) each study visit for any complications, problems or adverse events related to the study wound that they experience, such as maceration around the wound from the drainage, moisture, or dressing. Complications and adverse events will be compared during the course of the study

    Time frame: 12 weeks

  3. Pain in the wound and from dressing changes.

    Subjects with sensation in the area of the wound will be asked to complete a validated visual analogue scale. This is a simple validated test asking the subject to rate their pain on a 0-10 point level, where 10 is the worst and 0 is no pain. Mean and median pain scores will be compared for each treatment group during the course of the study

    Time frame: 12 weeks

  4. Wound Quality of Life

    Mean and median changes in validated Wound Quality of Life scores will be measured between groups during the course of the study

    Time frame: 12 weeks

07

Study locations

13 of 14 sites recruiting
  • San Diego VA
    San Diego, California 92161, United States
    Recruiting
    • Henry York, MD · ContactHenry.York@va.gov · 858-552-8585
    • Emily Sears · Contactesears@vmrf.org · 858-552-8585
    • Henry York, MD · Principal investigator
    • Melissa Brito, NP · Sub investigator
  • Medstar Georgetown University Hospital
    Washington D.C., District of Columbia 20007, United States
    Recruiting
  • MedStar National Rehabilitation Hospital
    Washington D.C., District of Columbia 20010, United States
    Recruiting
  • Northwestern Medicine
    Chicago, Illinois 60611, United States
    Active, not recruiting

    Not enrolling at this site.

  • Medstar Franklin Square Medical Center
    Baltimore, Maryland 21237, United States
    Recruiting
  • Medstar Good Samaritan Hospital
    Baltimore, Maryland 21239, United States
    Recruiting
  • Rutgers New Jersey Medical School, Ambulatory Care Center-Wound Care Clinic
    Newark, New Jersey 07103, United States
    Recruiting
  • Northwell Health System/Zucker School of Medicine
    Lake Success, New York 11042, United States
    Recruiting
    • Sally Kaplan, RN · Contactskaplan2@northwell.edu · 516-233-3781
    • Farisha Baksh · Contactfbaksh@northwell.edu · 516-233-3781
    • Alisha Oropallo, MD · Principal investigator
    • Christina Del Pin, MD · Sub investigator
    • Marisa Ranire-Maguire, MD · Sub investigator
    • Russell Caprioli, DPM · Sub investigator
    • John Haight, DPM · Sub investigator
    • Michael Pliskin, DPM · Sub investigator
    • Gawlik Scott, DPM · Sub investigator
  • NYU Langone Hospital-Long Island
    Mineola, New York 11501, United States
    Recruiting
  • James J. Peters VA Medical Center
    The Bronx, New York 10468, United States
    Recruiting
  • Westchester Medical Center, 100 Woods, Road, Taylor Care Pavillion
    Valhalla, New York 10595, United States
    Recruiting
  • University of Pittsburgh Medical Center (UPMC) Presbyterian
    Pittsburgh, Pennsylvania 15213, United States
    Recruiting
    • Cecilia Zamarripa, PhD, RN, CWON · Contactzamarripaca@upmc.edu · 412-647-7728
    • Bradley Good · Contactgoodb@upmc.edu · 412-647-7728
    • CeCe Zamarripa, PhD · Principal investigator
    • Gayle Gordillo, MD · Sub investigator
    • Amy Lynn Folk, RN, CWCN · Sub investigator
    • Constance Greco, DNP · Sub investigator
  • VA North Texas Healthcare System
    Dallas, Texas 75243, United States
    Recruiting
    • David Truong, DPM · ContactDavid.Truong1@va.gov · 214-857-2602
    • Morgan Williams · ContactMorgan.Williams5@va.gov · 214-857-2602
    • James Blaine, DPM · Sub investigator
    • Victoria Vo, DPM, MS · Sub investigator
    • Roger Bedimo, MD · Sub investigator
    • Anthony Ngoo, FNP · Sub investigator
    • Tonyka James, DPM · Sub investigator
  • Michael E. DeBakey Houston VAMC
    Houston, Texas 77030, United States
    Recruiting
    • Aimee Garcia, MD · ContactAimee.Garcia@va.gov · 512-387-1876
    • Felipe Salinas Martinez · ContactFelipe.SalinasMartinez@va.gov · 512-387-1876
    • Delma Jara, MD · Sub investigator
    • Ana Macias · Sub investigator
    • Sarwat Jabeen, MD · Sub investigator
08

References and documents

Publications

  • European Pressure Ulcer Advisory Panel, National Pressure Injury Advisory Panel and Pan Pacific Pressure Injury Alliance. Prevention and Treatment of Pressure Ulcers/Injuries: Clinical Practice Guideline. The International Guideline. Emily Haesler (ed.). EPUAP/NPIAP/PPPIA: 2019.
  • Mervis JS, Phillips TJ. Pressure ulcers: Pathophysiology, epidemiology, risk factors, and presentation. J Am Acad Dermatol. 2019 Oct;81(4):881-890. doi: 10.1016/j.jaad.2018.12.069. Epub 2019 Jan 18. PubMed 30664905 ↗
  • Essex HN, Clark M, Sims J, Warriner A, Cullum N. Health-related quality of life in hospital inpatients with pressure ulceration: assessment using generic health-related quality of life measures. Wound Repair Regen. 2009 Nov-Dec;17(6):797-805. doi: 10.1111/j.1524-475X.2009.00544.x. PubMed 19903301 ↗
  • Sebba Tosta de Souza DM, Veiga DF, Santos ID, Abla LE, Juliano Y, Ferreira LM. Health-Related Quality of Life in Elderly Patients With Pressure Ulcers in Different Care Settings. J Wound Ostomy Continence Nurs. 2015 Jul-Aug;42(4):352-9. doi: 10.1097/WON.0000000000000142. PubMed 26135820 ↗
  • https://www.ahrq.gov/patient safety/settings/hospital/resource/pressureulcer/tool/pu1.html#:~:text=Cost%3A%20Press ure%20ulcers%20cost%20%249.1,related%20to%20pressure%20ulcers%20annually.

Individual participant data

Plan to share: No

09

Timeline

Tracking since Sep 25, 2026
ElapsedEstimatedEstimated, not yet reachedSimilar studies: half by the dot; the band is the middle halfHalf of similar studies reached it by the dot; the band is the middle half, from a quarter to three quarters

Started Apr 2023 (actual). Primary completion is estimated for Dec 2026, 44 months after the start.

Of 29 industry-sponsored interventional studies with no phase under Pressure Ulcer, half reached primary completion within 15 months of starting (the median), counting those still running; a quarter within 8 and three quarters within 27. This study's planned 44 months is above that.

Counting every sponsor, half of 210 studies reached it within 11 months; a quarter within 5 and three quarters within 28.

How these figures are worked out, and which studies are left out of them.

Registered
Aug 8, 2022
First posted
Aug 11, 2022
StartActual
Apr 30, 2023
Primary completionEst.
Dec 2026
CompletionEst.
Dec 2026
Last update
Nov 20, 2025
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
No changes since tracking began. The registry record was last updated on Nov 20, 2025, before this site started recording changes on Sep 25, 2026. Its history is on ClinicalTrials.gov ↗
10

Registry details

Key details

Study ID
NCT05496296
Lead sponsor
ULURU Inc.
Collaborators
United States Department of Defense
Responsible party
Sponsor
First posted
Aug 11, 2022
Start date
Apr 30, 2023
Primary completion
Dec 2026 (estimated)
Completion
Dec 2026 (estimated)
Last update
Nov 20, 2025

Study contacts

Kerry Wallace
Contact
kwallace@altrazeal.com
513 702 7536
Susan St. John, MSN
Contact
sstjohn@altrazeal.com
Saxe Johathan, MD
principal investigator · Altrazeal Life Sciences Inc

Oversight

Data monitoring committee
No
FDA-regulated drug
No
FDA-regulated device
Yes
View the source record on ClinicalTrials.gov ↗

Interested in this study?

Eligibility is decided by the study team. Share this record with your doctor or contact the team directly.

Contact study team

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Start the discussion